AR030190A1 - Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo - Google Patents
Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararloInfo
- Publication number
- AR030190A1 AR030190A1 ARP010100659A ARP010100659A AR030190A1 AR 030190 A1 AR030190 A1 AR 030190A1 AR P010100659 A ARP010100659 A AR P010100659A AR P010100659 A ARP010100659 A AR P010100659A AR 030190 A1 AR030190 A1 AR 030190A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidinone
- manufacture
- pharmaceutically acceptable
- acceptable salt
- medicines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una pirimidinona que es 1-(N-(2-(dietilamino)etil)-N-(4-(4-trifluormetilfenil)bencil)aminocarbonilmetil)-2-(4-fluorbencil)tio-5,6-trimetilenpirimidin-4-ona o una sal farmacéuticamente aceptable de la misma. Dicha pirimidinona es un inhibidor de la enzima Lp-PLA2 y se usa en el tratamiento de desordenes tales como la arteriosclerosis. También se dan a conocer procedimientos para su preparacion, composiciones farmacéuticas que la contienen y su uso en la fabricacion de medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0003636A GB0003636D0 (en) | 2000-02-16 | 2000-02-16 | Novel compounds |
GB0101437A GB0101437D0 (en) | 2001-01-19 | 2001-01-19 | Novel Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030190A1 true AR030190A1 (es) | 2003-08-13 |
Family
ID=26243663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100659A AR030190A1 (es) | 2000-02-16 | 2001-02-14 | Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo |
Country Status (32)
Country | Link |
---|---|
US (10) | US20020103213A1 (es) |
EP (2) | EP1686119B1 (es) |
JP (1) | JP4095804B2 (es) |
KR (1) | KR100781425B1 (es) |
CN (1) | CN1179952C (es) |
AR (1) | AR030190A1 (es) |
AT (2) | ATE437862T1 (es) |
AU (2) | AU2001235466B2 (es) |
BG (1) | BG66014B1 (es) |
BR (1) | BRPI0108396B1 (es) |
CA (1) | CA2400554C (es) |
CO (1) | CO5271661A1 (es) |
CY (2) | CY1105649T1 (es) |
CZ (1) | CZ304450B6 (es) |
DE (2) | DE60121550T2 (es) |
DK (2) | DK1686119T3 (es) |
ES (2) | ES2330552T3 (es) |
GC (1) | GC0000221A (es) |
HK (1) | HK1053466A1 (es) |
HU (1) | HU229479B1 (es) |
IL (2) | IL151236A (es) |
MX (1) | MXPA02008062A (es) |
MY (1) | MY135732A (es) |
NO (1) | NO324691B1 (es) |
NZ (1) | NZ520752A (es) |
PL (1) | PL209824B1 (es) |
PT (2) | PT1686119E (es) |
SI (2) | SI1263740T1 (es) |
SK (1) | SK287296B6 (es) |
TW (1) | TW550259B (es) |
UA (1) | UA73762C2 (es) |
WO (1) | WO2001060805A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ520752A (en) * | 2000-02-16 | 2004-03-26 | Smithkline Beecham P | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
KR100823908B1 (ko) * | 2000-10-20 | 2008-04-21 | 바이오비트럼 에이비(피유비엘) | 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도 |
GB0119795D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127141D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
WO2003057671A1 (fr) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Compose biaryle et son utilisation |
US6939863B2 (en) | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
JP4366122B2 (ja) * | 2003-06-24 | 2009-11-18 | 日立オムロンターミナルソリューションズ株式会社 | 紙葉類搬送装置 |
GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
CN1875002B (zh) | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
EP1745033A4 (en) | 2004-05-08 | 2009-08-26 | Neurogen Corp | 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5 |
DE102004061005A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Cycloalkyl-1,2,4-triazin-5(2H)-one |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
WO2008140449A1 (en) | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
BRPI0810336A2 (pt) * | 2007-05-11 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
US8637524B2 (en) | 2009-07-28 | 2014-01-28 | Auspex Pharmaceuticals, Inc | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 |
UY33388A (es) * | 2010-05-17 | 2011-12-01 | Glaxo Group Ltd | Nuevos procesos para la preparacion de compuestos de pirimidinona |
JP6053675B2 (ja) | 2010-06-18 | 2016-12-27 | ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ | 抗ウイルス化合物のためのターゲットとしてのpla2g16 |
ES2559224T3 (es) * | 2010-12-06 | 2016-02-11 | Glaxo Group Limited | Compuestos de pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por Lp-PLA2 |
EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | LINKS |
CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
CN102643269B (zh) * | 2011-02-21 | 2014-07-23 | 天津药物研究院 | 一类含吡唑结构的磷脂酶a2抑制剂及用途 |
WO2012122707A1 (zh) * | 2011-03-16 | 2012-09-20 | 中国科学院上海药物研究所 | 季铵盐类化合物、其制备方法、药物组合物及用途 |
WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
JP2014521611A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | Lp−PLA2阻害剤としての2,3−ジヒドロイミダゾ[1,2−c]ピリミジン−5(1H)−オン化合物の使用 |
JP2014521625A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | 二環式ピリミドン化合物 |
CA2899143A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
CA2899124A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2015087239A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Processes for the preparation of darapladib and its intermediates |
WO2015092687A2 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Process for the purification of darapladib |
WO2015114479A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
CN105777653A (zh) | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
US10464896B2 (en) * | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
MX2018007155A (es) * | 2015-12-16 | 2018-08-15 | Squibb Bristol Myers Co | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj). |
US10878307B2 (en) * | 2016-12-23 | 2020-12-29 | Microsoft Technology Licensing, Llc | EQ-digital conversation assistant |
US11583596B2 (en) | 2017-09-26 | 2023-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds |
CN110746445B (zh) * | 2019-10-16 | 2021-03-16 | 深圳海关食品检验检疫技术中心 | 一种头孢哌酮氘代内标物的制备方法 |
WO2021089032A1 (zh) | 2019-11-09 | 2021-05-14 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
EP4257133A1 (en) | 2022-04-05 | 2023-10-11 | Institut Pasteur | Oxo-azaheterocyclic derivatives for use in the treatment of malaria |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500740A (ja) | 1993-06-25 | 1996-01-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | リポタンパク質関連ホスホリパーゼa▲下2▼、その阻害剤および診断および治療におけるその使用 |
EP1634953A3 (en) * | 1993-10-06 | 2006-06-28 | ICOS Corporation | Platelet-activating factor acethylhydrolase |
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
HUT77089A (hu) | 1994-12-22 | 1998-03-02 | Smithkline Beecham Plc. | Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
EP0840725A1 (en) | 1995-07-01 | 1998-05-13 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
AU7216996A (en) | 1995-09-29 | 1997-04-28 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
WO1997021675A1 (en) | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
IL126696A0 (en) | 1996-04-26 | 1999-08-17 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
EP1028955B1 (en) | 1997-11-06 | 2003-07-16 | SmithKline Beecham plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
ATE251613T1 (de) * | 1998-08-21 | 2003-10-15 | Smithkline Beecham Plc | Pyrimidinonderivate zur behandlung von atheroscleros |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
AU766003B2 (en) * | 1999-05-01 | 2003-10-09 | Smithkline Beecham Plc | Pyrimidinone compounds |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
NZ520752A (en) * | 2000-02-16 | 2004-03-26 | Smithkline Beecham P | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
-
2001
- 2001-02-13 NZ NZ520752A patent/NZ520752A/en not_active IP Right Cessation
- 2001-02-13 ES ES06075890T patent/ES2330552T3/es not_active Expired - Lifetime
- 2001-02-13 ES ES01907522T patent/ES2267714T3/es not_active Expired - Lifetime
- 2001-02-13 MX MXPA02008062A patent/MXPA02008062A/es active IP Right Grant
- 2001-02-13 AT AT06075890T patent/ATE437862T1/de active
- 2001-02-13 CA CA002400554A patent/CA2400554C/en not_active Expired - Fee Related
- 2001-02-13 DE DE60121550T patent/DE60121550T2/de not_active Expired - Lifetime
- 2001-02-13 PT PT06075890T patent/PT1686119E/pt unknown
- 2001-02-13 CN CNB01806521XA patent/CN1179952C/zh not_active Expired - Fee Related
- 2001-02-13 UA UA2002097389A patent/UA73762C2/uk unknown
- 2001-02-13 SK SK1177-2002A patent/SK287296B6/sk not_active IP Right Cessation
- 2001-02-13 WO PCT/EP2001/001515 patent/WO2001060805A1/en active Application Filing
- 2001-02-13 PL PL357382A patent/PL209824B1/pl unknown
- 2001-02-13 HU HU0204410A patent/HU229479B1/hu not_active IP Right Cessation
- 2001-02-13 DE DE60139429T patent/DE60139429D1/de not_active Expired - Lifetime
- 2001-02-13 AT AT01907522T patent/ATE333446T1/de active
- 2001-02-13 AU AU2001235466A patent/AU2001235466B2/en not_active Ceased
- 2001-02-13 KR KR1020027010662A patent/KR100781425B1/ko not_active IP Right Cessation
- 2001-02-13 EP EP06075890A patent/EP1686119B1/en not_active Expired - Lifetime
- 2001-02-13 EP EP01907522A patent/EP1263740B1/en not_active Expired - Lifetime
- 2001-02-13 JP JP2001560190A patent/JP4095804B2/ja not_active Expired - Fee Related
- 2001-02-13 DK DK06075890T patent/DK1686119T3/da active
- 2001-02-13 AU AU3546601A patent/AU3546601A/xx active Pending
- 2001-02-13 CZ CZ2002-2768A patent/CZ304450B6/cs not_active IP Right Cessation
- 2001-02-13 PT PT01907522T patent/PT1263740E/pt unknown
- 2001-02-13 SI SI200130614T patent/SI1263740T1/sl unknown
- 2001-02-13 DK DK01907522T patent/DK1263740T3/da active
- 2001-02-13 BR BRPI0108396-1A patent/BRPI0108396B1/pt not_active IP Right Cessation
- 2001-02-13 SI SI200130941T patent/SI1686119T1/sl unknown
- 2001-02-14 US US09/782,930 patent/US20020103213A1/en not_active Abandoned
- 2001-02-14 GC GCP20011178 patent/GC0000221A/en active
- 2001-02-14 AR ARP010100659A patent/AR030190A1/es not_active Application Discontinuation
- 2001-02-14 MY MYPI20010671A patent/MY135732A/en unknown
- 2001-02-15 CO CO01011957A patent/CO5271661A1/es active IP Right Grant
- 2001-02-15 TW TW090103332A patent/TW550259B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 NO NO20023828A patent/NO324691B1/no not_active IP Right Cessation
- 2002-08-13 IL IL151236A patent/IL151236A/en not_active IP Right Cessation
- 2002-08-26 BG BG107034A patent/BG66014B1/bg unknown
-
2003
- 2003-02-03 US US10/357,238 patent/US6649619B1/en not_active Expired - Lifetime
- 2003-06-09 HK HK03104052A patent/HK1053466A1/xx not_active IP Right Cessation
- 2003-10-27 US US10/694,561 patent/US7153861B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 CY CY20061101441T patent/CY1105649T1/el unknown
- 2006-11-17 US US11/561,035 patent/US7470694B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/561,926 patent/US7638520B2/en not_active Expired - Fee Related
-
2007
- 2007-03-15 IL IL181957A patent/IL181957A0/en unknown
-
2009
- 2009-01-06 US US12/349,086 patent/US7652019B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,837 patent/US20090170877A1/en not_active Abandoned
- 2009-10-12 CY CY20091101045T patent/CY1109484T1/el unknown
-
2010
- 2010-02-18 US US12/707,838 patent/US20100144765A1/en not_active Abandoned
-
2011
- 2011-12-02 US US13/309,941 patent/US8871775B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,870 patent/US9266841B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030190A1 (es) | Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo | |
CR10114A (es) | Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687) | |
ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
MY144659A (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
CY1109523T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv | |
ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
ECSP034774A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
ECSP045519A (es) | Nuevos derivados de quinuclidina-amida | |
NO20043531L (no) | Indazolforbindelser som er nyttige som proteinkinaseinhibitorer | |
ECSP088404A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores de la glucógeno sintasa quinasa 3, para uso en el tratamiento de demencia y trastornos neurodegenerativos | |
NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
BRPI0607811B8 (pt) | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso | |
AR078951A1 (es) | Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea | |
UY31866A (es) | Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones | |
AR033293A1 (es) | Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos | |
DOP2005000085A (es) | Composicion farmaceutica antimicobacterial | |
ATE253359T1 (de) | Antithrombotische mittel | |
AR038858A1 (es) | Combinacion | |
DK1497292T3 (da) | Azaindolylpiperidinderivater som antihistamin- og antiallergimidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |